PURPOSE: To describe the clinical phenotype in a family with Best's vitelliform macular dystrophy (BMD) and a new mutation (Val89Ala) in the VMD2 gene. METHODS: The genotype was determined by direct sequence analysis of the individual exons of VMD2. Nine members of a family with BMD were examined. The examination included best-corrected visual acuity, electro-oculography (EOG), fundus examination, and photography. Four of the patients were also examined with full-field ERG and three with multifocal ERG. RESULTS: A T-to-C substitution was identified at position 370 in the cDNA of VMD2, leading to a Val89Ala change in the protein. Six patients, five with the Val89Ala mutation and a nine-year-old boy without the mutation, presented with a pathological Arden ratio on EOG examination. Most of the patients with BMD in this family had an onset of visual failure by the age of 40-50 years. The older patients in the family demonstrated atrophic macular dystrophy. CONCLUSIONS: Patients with BMD and the Val89Ala mutation in the VMD2 gene can present with a phenotype of a mostly late-onset visual failure. These BMD patients, who present with visual failure and macular degeneration in middle age, can be misdiagnosed as being affected with adult-onset macular dystrophies instead of BMD, because the latter is often regarded as a disease of childhood and adolescence.
PURPOSE: To describe the clinical phenotype in a family with Best's vitelliform macular dystrophy (BMD) and a new mutation (Val89Ala) in the VMD2 gene. METHODS: The genotype was determined by direct sequence analysis of the individual exons of VMD2. Nine members of a family with BMD were examined. The examination included best-corrected visual acuity, electro-oculography (EOG), fundus examination, and photography. Four of the patients were also examined with full-field ERG and three with multifocal ERG. RESULTS: A T-to-C substitution was identified at position 370 in the cDNA of VMD2, leading to a Val89Ala change in the protein. Six patients, five with the Val89Ala mutation and a nine-year-old boy without the mutation, presented with a pathological Arden ratio on EOG examination. Most of the patients with BMD in this family had an onset of visual failure by the age of 40-50 years. The older patients in the family demonstrated atrophic macular dystrophy. CONCLUSIONS:Patients with BMD and the Val89Ala mutation in the VMD2 gene can present with a phenotype of a mostly late-onset visual failure. These BMDpatients, who present with visual failure and macular degeneration in middle age, can be misdiagnosed as being affected with adult-onset macular dystrophies instead of BMD, because the latter is often regarded as a disease of childhood and adolescence.
Authors: Elliott H Sohn; Peter J Francis; Jacque L Duncan; Richard G Weleber; David A Saperstein; Donald F Farrell; Edwin M Stone Journal: Arch Ophthalmol Date: 2009-07